United Therapeutics Corporation (NASDAQ:UTHR) — Market Cap & Net Worth
Market Cap & Net Worth: United Therapeutics Corporation (UTHR)
United Therapeutics Corporation (NASDAQ:UTHR) has a market capitalization of $21.42 Billion ($21.42 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1212 globally and #506 in its home market, demonstrating a 2.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying United Therapeutics Corporation's stock price $500.35 by its total outstanding shares 43056599 (43.06 Million). Also see UTHR asset base for a full breakdown of the balance sheet.
United Therapeutics Corporation Market Cap History: 2015 to 2026
United Therapeutics Corporation's market capitalization history from 2015 to 2026. Data shows growth from $6.74 Billion to $21.54 Billion (13.40% CAGR). Also see cash efficiency ratio of United Therapeutics Corporation for how efficiently the company converts equity into cash flow.
Index Memberships
United Therapeutics Corporation is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 2.03% | #13 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 1.85% | #9 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.81% | #20 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.05% | #149 of 3165 |
|
S&P Midcap 400
MID
|
$3.41 Trillion | 0.50% | #11 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 1.14% | #14 of 263 |
Weight: United Therapeutics Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
United Therapeutics Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how United Therapeutics Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check United Therapeutics Corporation stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.28x
United Therapeutics Corporation's market cap is 5.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.71x
United Therapeutics Corporation's market cap is 12.71 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $6.74 Billion | $1.47 Billion | $651.64 Million | 4.60x | 10.35x |
| 2016 | $6.18 Billion | $1.60 Billion | $713.70 Million | 3.86x | 8.65x |
| 2017 | $6.37 Billion | $1.73 Billion | $417.90 Million | 3.69x | 15.24x |
| 2018 | $4.69 Billion | $1.63 Billion | $589.20 Million | 2.88x | 7.96x |
| 2019 | $3.79 Billion | $1.45 Billion | -$104.50 Million | 2.62x | N/A |
| 2020 | $6.54 Billion | $1.48 Billion | $514.80 Million | 4.41x | 12.70x |
| 2021 | $9.30 Billion | $1.69 Billion | $475.80 Million | 5.52x | 19.55x |
| 2022 | $11.97 Billion | $1.94 Billion | $727.30 Million | 6.18x | 16.46x |
| 2023 | $9.47 Billion | $2.33 Billion | $984.80 Million | 4.07x | 9.61x |
| 2024 | $15.19 Billion | $2.88 Billion | $1.20 Billion | 5.28x | 12.71x |
Competitor Companies of UTHR by Market Capitalization
Companies near United Therapeutics Corporation in the global market cap rankings as of September 16, 2026. Review United Therapeutics Corporation (UTHR) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to United Therapeutics Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
United Therapeutics Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, United Therapeutics Corporation's market cap moved from $6.74 Billion to $ 21.54 Billion, with a yearly change of 13.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $21.54 Billion | +2.69% |
| 2025 | $20.98 Billion | +38.09% |
| 2024 | $15.19 Billion | +60.46% |
| 2023 | $9.47 Billion | -20.93% |
| 2022 | $11.97 Billion | +28.70% |
| 2021 | $9.30 Billion | +42.35% |
| 2020 | $6.54 Billion | +72.33% |
| 2019 | $3.79 Billion | -19.12% |
| 2018 | $4.69 Billion | -26.39% |
| 2017 | $6.37 Billion | +3.15% |
| 2016 | $6.18 Billion | -8.42% |
| 2015 | $6.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of United Therapeutics Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.42 Billion USD |
| MoneyControl | $21.42 Billion USD |
| MarketWatch | $21.42 Billion USD |
| marketcap.company | $21.42 Billion USD |
| Reuters | $21.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer;… Read more